Although there has been a lot of noise reverberating throughout the cannabis community this year, regarding the U.S. Drug Enforcement Administration’s supposed decision over whether to downgrade the Schedule I listing of the cannabis plant, there is increasing evidence that Uncle Sam’s dope-sniffing henchmen, along with a gang of apprehensive federal lawmakers, are scheming up a plan to only unleash that part of the herb that doesn’t get people high.
The stoner nation went absolutely berserk back in April when the DEA revealed through a letter to Senator Elizabeth Warren that the agency was planning to announce a possible Schedule downgrade for the cannabis plant before the end of summer. While the 25-page document did not give any indication as to how this potential amendment to the Controlled Substances Act would be made, the majority of the folks swallowing the news took it as an implication that legalization was right around the corner.
Unfortunately, some of the latest chatter coming from DEA insiders alludes to the possibility that the agency is only considering a reschedule for Cannabidiol or CBD, the non-intoxicating part of the cannabis plant that has been making headlines for the past few years for its effectiveness in treating seizure disorders.
A recent interview with DEA staff coordinator Russ Baer suggests that the agency is struggling over how “complex the marijuana plant is” because it contains “hundreds of chemical actors, or cannabinoids.” Baer said that it has been challenging for the federal government to “identify the parts of the plant that might have benefit, and separating out (the beneficial) components and distinguishing which “aren’t beneficial or harmful.”
So while it has been proven over the course of the past several decades that marijuana is, in fact, safer than America’s leading legal drugs — alcohol, tobacco, and even caffeine – it sounds as though the federal government is currently dissecting the cannabis plant in an effort to appease the call for “medicine,” while it continues to criminalize THC.
But it’s not just the DEA that is scheming to simply loosen the reigns on that element of the cannabis plant that does not produce psychoactive effects. Four members of the U.S. Senate Judiciary Committee, including anti-pot politician Senator Chuck Grassley, recently introduced a bill called the Cannabidiol Research Expansion Act (S.3269), which would “require the Attorney General to make a determination as to whether cannabidiol should be a controlled substance” and “expand research on the potential medical benefits of cannabidiol” as a drug. But it would not provide the same luxury for those of the scientific community wishing to study the medicinal benefits of THC. Cannabidiol would be considered a completely separate substance from the cannabis plant.
Senator Grassley, who has refused to give better bills, like CARERS Act, so much as a hearing, recently implied that it was the nagging of medical marijuana advocates, specifically those begging lawmakers to give them access to cannabis oil, that prompted him to get behind this modest step toward a nation of legal medical marijuana.
“The parents of children with severe epilepsy and other conditions are interested in cannabidiol to try to ease their children’s symptoms,” Grassley said in a recent press statement. “I understand their interest. Research is necessary to determine the potential medical value of cannabidiol, and wherever possible, the government should help facilitate the scientific research needed to give these parents the answers they need.”
But the bill is flimsy, to say the least.
While it comes with a “safe harbor” clause that would prevent the “legal guardian” of a child suffering from “intractable epilepsy” from being prosecuted under federal law for possession of CBD, it would do nothing to protect patients with other conditions, nor would it have any impact on pot products containing any amount of THC. This means most people, even medical marijuana patients, would continue to go to jail for weed.
Interestingly, this proposed policy is similar to what Baer has implied is being examined by the DEA – dissecting cannabis for good and evil.
Over half the nation has legalized marijuana for medicinal purposes, but for some reason the United States government continues to refuse any level of nationwide reform. From the DEA’s indecision over whether to reschedule portions, all, or none of the plant, to federal lawmakers deeming it necessary to first test the therapeutic benefits of the plant’s non-intoxicating properties before calling it medicine, the brass in Washington D.C. continue to jam up progress on an issue that is already being widely received by over a million citizens.
Family of Man Killed by Bulldozer After Growing Pot Sues Police
Ban on Smokable Medical Marijuana Officially Repealed in Florida
High Folks: Yareem Barnes-Ivey Balances the Two Worlds of Cannabis
The High Priestess: What to Smoke For Spring
Knowledgeable Dabbing: A Guide To Our Favorite Quartz Bangers
First Clinical Trial Of Cannabis For PTSD in Veterans Is Now Complete
Missouri Police Raid Hospital Room of Stage 4 Cancer Patient Using Cannabis
Oklahoma House Passes Medical Cannabis Protection Bill
News4 days ago
Indiana State Trooper Seizes $3.5 Million Worth of Cannabis, Vapes
News4 days ago
Colorado Researchers Seeking Volunteers to Get High and Drive
News5 days ago
Study Finds Medical Marijuana Alleviates Seniors’ Pain, Reduces Opioid Use
News6 days ago
Survey Shows 25% of Cannabis Users in Legal States Consume at Work
Legalization5 days ago
Breaking: Connecticut Lawmakers Unveil Plan to Legalize Marijuana
Culture4 days ago
The New “Miss Marijuana” Pageant Comes With Outdated Guidelines and Transphobia
News6 days ago
$2.5 Million Worth of Marijuana Seized at Philadelphia Port
Grow5 days ago
An Interview With Dinafem Seeds: Europe’s King Of Feminized Seeds